Presentation is loading. Please wait.

Presentation is loading. Please wait.

APRE Agenzia per la promozione della Ricerca Europea Caterina Buonocore, Health National Contact Point for Italy, Part of this presentation is taken from.

Similar presentations


Presentation on theme: "APRE Agenzia per la promozione della Ricerca Europea Caterina Buonocore, Health National Contact Point for Italy, Part of this presentation is taken from."— Presentation transcript:

1 APRE Agenzia per la promozione della Ricerca Europea Caterina Buonocore, Health National Contact Point for Italy, Part of this presentation is taken from the official material produced by EC, DG Research, Unit F.

2 AGENDA PRESENTAZIONE APRE SETTIMO PROGRAMMA QUADRO (7PQ) 1.Structure and scope of Health theme 2.Basic principles 3.Health 2013 Work programme key features / priorities 4.How to find partners 5.Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH, ENV… 6.Other funding opportunities for health researchers 7.Information sources

3 [COSÉ APRE?] L' APRE è un Ente di ricerca non profit con obiettivo, sancito dallarticolo 3 del suo statuto, di promuovere la partecipazione italiana ai programmi di ricerca e sviluppo finanziati dalla Commissione Europea. È sostenuta da numerose Università e organizzazioni private e pubbliche del mondo accademico, dellindustria e della finanza. Prima realtà del suo genere in Italia, APRE nasce nel 1989 come Task Force del Ministero dellUniversità e della Ricerca. Nel 1990 viene poi costituita formalmente da Confindustria, ENEA, FAST e Mondimpresa

4 [MISSION]

5 [INTERLOCUTORI] APRE Associazioni industiali Camere di Commercio Parchi Scientifici Università Centri di ricerca Industrie Enti pubblici Finanza Soci APRE

6 [RISORSE APRE – SPORTELLI LOCALI] Per rafforzare il sistema della cooperazione tra istituzioni pubbliche e private attive nel settore della ricerca scientifica e tecnologica e promuovere e diffondere la ricerca europea a livello nazionale, APRE dispone di una rete di Sportelli regionali. Gli Sportelli, oltre a fornire tutti i servizi specifici dell'APRE, costituiscono anche una sede per favorire le iniziative promosse dai Soci APRE presenti nella regione, supportando inoltre quelle portate avanti da parte di altre istituzioni ed organizzazioni impegnate nel campo della ricerca e dell'innovazione tecnologica Ospitati e gestiti dai Soci APRE, gli Sportelli APRE sono punti di accesso alle informazioni ad operatività regionale e coordinati dalla sede centrale a Roma.

7 [RISORSE APRE – SPORTELLO EUROPA] partecipazione ad eventi e giornate informative diffusione di informazioni aggiornate sulle politiche, iniziative ed opportunità sulla ricerca in Europa collegamento diretto con vari attori della ricerca Europea (Istituzioni Europee, liaison office e organismi di ricerca degli Stati Membri, Confederazioni e Consorzi paneuropei) accompagnamento agli incontri con i funzionari della Commissione Europea la sala riunione per meeting internazionali dei progetti Europei di ricerca APRE BRUSSEL offre ai soci:

8 [MISSION] Commissione Europea Rappresentanz a Italiana Delegati Nazionali PQ MIUR APRE (NCP) 1

9 Silvio Garattini (Mario Negri) Stefano Vella (ISS) Caterina Buonocore (APRE) Alfredo Cesario (IRCSS) PUNTI DI CONTATTO NAZIONALI Caterina Buonocore APRE Bruno Mourenza APRE COMITATO DI PROGRAMMA SALUTE IN ITALIA:

10 [MISSION] Proposta vincente Formazione Informazione Assistenza Essere un buon coordinatore Preparazione della proposta Come disseminare i risultati della ricerca Proprietà intellettuale e Consortium Agreement Essere un buon coordinatore Preparazione della proposta Come disseminare i risultati della ricerca Proprietà intellettuale e Consortium Agreement Formazione Conferenze News Alert Sito web ( www.apre.it)www.apre.it Pubblicazioni Conferenze News Alert Sito web ( www.apre.it)www.apre.it Pubblicazioni Informazione Identificazione del tema e del topic FP7 Verificare lelegibilità della proposta Pre-screening della proposta Aiuto nellutilizzo dellEPSS System Identificazione del tema e del topic FP7 Verificare lelegibilità della proposta Pre-screening della proposta Aiuto nellutilizzo dellEPSS System Supporto prima dellinizio del progetto (telefono, mail e incontri) Negoziazione Management del progetto Disseminazione dei risultati Reporting Negoziazione Management del progetto Disseminazione dei risultati Reporting Supporto dopo linizio del progetto (telefono, mail e incontri) APRE ospita i Punti di contatto nazionale del VII Programma Quadro in Italia. Questi sono nominati dal Ministero dell'Università e della Ricerca (MUR) e riconosciuti dalla Commissione Europea.

11 SALUTE NEL 7 PQ COME SCEGLIERE IL BANDO GIUSTO IN UN PANORAMA ARTICOLATO

12

13 The 7th Framework programme (FP7) 1.Structure and scope of Health theme 2.Basic principles 3. Health 2013 Work programme key features / priorities 4.Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH… 5.Other funding opportunities for health researchers 6.Information sources

14 EU research policy Why ? l to improve quality of life and l to improve competiveness of Europe through collaboration How ? l by pooling resources (funds for Framework Programme) l by coordinating national research programmes

15 Interlocutori Università PMI Industria IRCCS Ospedali Centri di ricerca Ricerca clinica [INTERLOCUTORI SALUTE] Associazioni di pazienti

16 Joint Research Centre (non-nuclear) Euratom JRC Euratom + + 16 FP7 © Fit for Health, 2012

17 17 R&D Chain © Fit for Health, 2012

18 EUROPEAN COMMISSION - Research DG 7th Framework Programme for Research Indicative breakdown ( million)

19 Collaborative research in the Health theme Budget: l 6.1 billion over 7 years (2007-2013) Main policy drivers: l Improving health of European citizens l Increasing competitiveness of European health-related industries and businesses l Addressing global health issues, including emerging epidemics

20 Collaborative research across borders and other barriers l between countries: è at least 3 partners from the 27 EU Member States: Austria, Belgium, Bulgaria, Czech Rep., Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Rumania, Slovakia, Slovenia, Spain, Sweden, the United Kingdom. è or the 12 Associated Countries: Albania, Bosnia-Herzegovina, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey. è In addition, researchers from anywhere in the world can participate: eg: Australia, Brazil, Canada, China, Egypt, India, Japan, Korea, Russia, South-Africa, USA, … and in many cases, can be funded.

21 Collaborative research across borders and other barriers l between countries but also: l between different types of organizations Public & private sector: universities, research centres, large companies, small and medium-sized enterprises (SMEs), etc. l between disciplines : multidisciplinary, translational R&D

22 1. Structure and scope of Health theme

23 The Health Theme Three main activities (pillars) Activity 1: Biotechnology, generic tools & technologies for health Activity 2: Translating research for human health Activity 3: Optimising the delivery of health care cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issues Activity 4: Support actions & response to policy needs The Innovative Medicines Initiative

24 EC Funding Strategy DiscoveryPreclinical Phase I/IIa Phase II + III Regulatory Regulatory EDCTP Large Collaborative Projects Research GrantsProduct development, PPP Translational research Clinical capacity Bottlenecks = Innovative Medicine Initiative (IMI)

25 Policy aspects Emphasis and special measures for: l Small & Medium-sized Enterprises (SMEs) è Opportunities and support measures l International Cooperation è the possibility to tackle issues on a global scale è an opportunity to extend your networks beyond Europe Industry (esp. SME) participation & International Cooperation

26 2. Basic Principles

27 Basic principles: l Annual calls for proposals (2-stage) l Evaluation by panels of independent experts overseen by Independent Observers l 3 criteria: Science & Technology excellence Implementation & Management Potential Impact l Feedback: Evaluation Summary Reports (ESRs) Submission & evaluation Experts wanted ! Aim: to fund the best R&D proposals

28 3. HEALTH 2013 Work Programme

29 Funding schemes for these calls Note: there are some exceptions to the ceilings.

30

31 Priorities for Health in 2012-2013 2013 thematic priorities: Brain research Anti-microbial resistance Comparative effectiveness (CER) Cross-cutting priorities: Translation of results into applications Innovation & SMEs Social innovation Social innovation refers to new strategies, concepts, ideas and organizations that meet social needs of all kinds - from working conditions and education to community development and health - and that extend and strengthen civil society.strategiesconceptsideas organizationssocialworking conditionseducationcommunity developmenthealthcivil society International cooperation

32 FP7-HEALTH-2013-INNOVATION-1 as main call with an indicative budget of EUR 680 million with broader topics of which many are tailored for SME participation (bottom-up with a minimum percentage of EU funding requested going to SMEs) FP7-HEALTH-2013-INNOVATION-2 as a specific call to boost SME participation for innovative solutions in the health sector with an indicative budget of EUR 140 million. This call has very specific conditions. Maximum project duration is limited to 3 years. HEALTH 2 STAGE EVALUATION. Max 6 pagine: 1.1 Concept and objectives 1.2 Progress beyond the state-of-the-art 1.3 S/T methodology and associated work plan 2.1 Expected impacts

33 Call identifier: FP7-HEALTH-2013-INNOVATION-1 35 topics Proposal submission and evaluation: two-stage procedure. Date of publication: 10 July 2012 Deadline for stage 1 proposals: 02 October 2012 at 17:00:00 (Brussels local time) Indicative budget: EUR 680 million from the 2013 budget 7 th CALL HEALTH Call identifier: FP7-HEALTH-2013-INNOVATION-2 2 topics Proposal submission and evaluation: two-stage procedure. Date of publication: 10 July 2012 Deadline for stage 1 proposals: 25 September 2012 at 17:00:00 (Brussels local time) Indicative budget: EUR 140 million from the 2013 budget

34 2013 WP preparation Milestones and meetings Roadmap discussed at PC meeting: 5 September 2011 Draft WP v1 (Orientation paper) => sent to PC by mid-October Meeting with Advisory Group (9 Nov 2011) PC meeting (9-10 Nov 2011) to discuss draft WP v1 PC meeting (14 Feb. 2012) to discuss draft WP v2 => final input by 24 February Internal draft must be ready by 12 March. Inter-service Consultation (April-May 2012) - draft WP v3 Formal PC consultation (June 2012) - draft WP v4 Work Programme adoption & publication: 10 July 2012

35 Health theme Cross cutting topic relevant to the entire Health theme 0-1 - Boosting the translation of FP projects' results into innovative applications for health. FP7-Health-2013-INNOVATION-2 build on the results of projects funded under Health theme of FP6 & FP7. focus on specifications, testing and validation of results applicants must control the IPR to be used in their application New: SMEs must be from Member States or Associated Countries (conditions specified, further changes to come based on INNOV-2 call) Funding scheme:CP-FP, max. 6m/project. MS & AC SMEs only. SME-topic: min. 50% EC contribution to SMEs Indicative budget: 75 million

36 The Health theme 1: Biotechnology, generic tools and medical for technologies for human health 1.1 High-throughput research (closed) 1.2 Detection, diagnosis and monitoring 1.3 Suitability, safety and efficacy of therapies 1.4 Innovative therapeutic approaches and interventions

37 Area 1.2 Detection, Diagnosis and Monitoring

38 Activity 1 Biotech, tools & technologies 1.2 – Detection, Diagnosis & Monitoring 1.2-1 - Development of imaging technologies for therapeutic interventions in rare diseases. Funding scheme:CP-FP, max. 6m/project. SME-topic: min. 30% EC contribution to SMEs

39 Area 1.3 Suitability, Safety and Efficacy of Medicines

40 Activity 1 Biotech, tools & technologies 1.3 – Suitability, safety & efficacy of medicines 1.3-1 - Modelling toxic responses in case studies for predictive human safety assessment. Funding scheme:CP-FP, max. 12m/project. Industry topic: min. 15% EC contribution to industry, incl. SMEs Only one proposal may be selected 1.3-2 - Innovative approaches to address adverse immune reactions to biomedical devices, implants & transplant tissues. Funding scheme:CP-FP, max. 6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs

41 Activity 1 Biotech, tools & technologies 1.3 – Suitability, safety & efficacy of medicines 1.3-3 - Safety and efficacy of therapeutic vaccines. Funding scheme:CP-FP, max. 6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs 1.3-4 - Development of alternative in vitro, analytical, immunochemical, and other test methods for quality control of vaccines. Funding scheme:CP-FP, max. 6m/project. New: max. 3 years SME topic: min. 30% EC contribution to SMEs

42 Area 1.4 Innovative therapeutic approaches and interventions

43 Activity 1 Biotech, tools & technologies 1.4-1 - Controlling differentiation and proliferation in human stem cells intended for therapeutic use. Funding scheme:CP-FP, max. 6m/project. SME topic: min. 15% EC contribution to SMEs

44 The Health theme 2: Translating research for human health 2.1 Integrating biological data and processes: large-scale data gathering, systems biology 2.2 Research on the brain and related diseases, human development and ageing 2.3 Translational research in major infectious diseases: to confront major threats to public health 2.4 Translational research in other major diseases

45 Area 2.1.1 Large-scale data gathering

46 Activity 2 - Translating research for human health 2.1.1 – Large-scale data gathering 2.1.1-1 - Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes. Funding scheme:CP-IP, max. 12m/project. SME topic: min. 30% EC contribution to SMEs 2.1.1-2 - High impact research initiative on metagenomics for personalised medicine approaches. Funding scheme:IP, max. 30m/project; max. 1 project Industry topic: min. 30% EC contribution to industry, incl. SMEs Only one proposal may be selected

47 Area 2.2.1 Research on the brain and brain related diseases

48 Activity 2 - Translating research for human health 2.2.1-1 - Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI) Funding scheme:CP-IP, max. 30m/project, one or more projects 2.2.1-2 - Development of effective imaging tools for diagnosis, monitoring and management of mental disorders Funding scheme:CP-FP, max. 6m/project Industry topic: min. 30% EC contribution to industry, incl. SMEs

49 Activity 2 - Translating research for human health 2.2.1 – The brain and brain disorders 2.2.1-3 - Paediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatment Funding scheme:CP-FP, max. 6m/project SME topic: min. 15% EC contribution to SMEs 2.2.1-4 - Patho-physiology and therapy of epilepsy and epileptiform disorders Funding scheme:CP-IP, max. 12m/project SME topic: min. 15% EC contribution to SMEs 2.2.1-5 – Understanding and combating pain (NEW) Funding scheme:CP-FP, max. 6m/project

50 Area 2.3 Translational research in major infectious diseases; to confront major threats to public health 2.3.0 – Cross cutting issues 2.3.1 – Antimicrobial drug resistance 2.3.2 – HIV/AIDS, malaria, tuberculosis (closed) 2.3.3 – Potentially new & re-emerging epidemics 2.3.4 – Neglected infectious diseases

51 Activity 2 - Translating research for human health 2.3.0 – Cross-cutting priorities 2.3.0-1 – Innovation in vaccines Funding scheme:CP-FP, max. 6m/project. SME topic: min. 30% EC contribution to SMEs

52 Activity 2 - Translating research for human health 2.3.1 – Anti-microbial drug resistance 2.3.1-2 - Stratified approaches to antibacterial and/or antifungal treatment Funding scheme:CP-FP, max. 6m/project. 2.3.1-1 – INNOVATION 2 Drugs and vaccines for infections that have developed or are at risk of developing significant antimicrobial resistance. New: SMEs must be from Member States or Associated Countries Funding scheme:CP-FP, max. 6m/project. MS & AC SMEs only. SME topic: min. 50% EC contribution to SMEs

53 Activity 2 - Translating research for human health 2.3.3 – Potentially new and re-emerging epidemics 2.3.3-1 – Clinical management of patients in severe epidemics. Funding scheme:IP, max. 24m/project; max. 1 project

54 Activity 2 - Translating research for human health 2.3.4 – Neglected infectious diseases 2.3.4-1 – Neglected infectious diseases of Central and Eastern Europe. Funding scheme:FP, max. 6m/project. SME topic: min. 15% EC contribution to SMEs 2.3.4-2 – Drug development for neglected parasitic diseases. Funding scheme:FP, max. 3m/project.

55 Area 2.4 Translational research in other major diseases 2.4.1 – Cancer 2.4.2 – CVD 2.4.3 – Diabetes/obesity (closed) 2.4.4 – Rare diseases (closed) 2.4.5 – Chronic diseases (closed)

56 Activity 2 - Translating research for human health 2.4.1 – Cancer 2.4.1-1 – Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer. Funding scheme:CP-FP, max. 6m/project. 2.4.1-2 – Strengthening the cancer patient's immune system. Funding scheme:CP-FP, max. 6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs 2.4.1-3 - Investigator-driven supportive and palliative care clinical trials and observational studies. Funding scheme:CP-FP, max. 6m/project.

57 Activity 2 - Translating research for human health 2.4.2 – Cardiovascular diseases 2.4.2-1 – Discovery research to reveal novel targets for cardiovascular disease treatment. Funding scheme:CP-FP, max. 6m/project. SME topic: min. 30% EC contribution to SMEs 2.4.2-2 – Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases. Funding scheme:CP-FP, max. 6m/project. 2.4.2-3: Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan. Funding scheme:CP-FP, Small 3m/project.

58 The Health Theme 3: Optimising the delivery of healthcare to European citizens 3.1 Translating clinical research into clinical practice 3.2 Quality, efficiency and solidarity of healthcare systems (closed) 3.3 Health promotion and prevention 3.4 International public health & health systems (closed)

59 Activity 3 Optimising the delivery of healthcare 3.1 – Translating clinical research into clinical practice 3.1-1 - Comparative Effectiveness Research (CER) in health systems and health services interventions. Funding scheme:CP-FP, max. 6m/project. 3.3 – Health promotion and prevention 3.3-1 - Social innovation for health promotion Funding scheme:CP-FP, max. 6m/project. SME topic: min. 15% EC contribution to SMEs

60 The Health theme 4: Actions across the Theme 4.1 Coordination & Support Actions across the theme 4.2 Responding to EU policy needs

61 Activity 4 Actions across the theme 4.1 – CSAs across the theme 4.1-1 –Supporting industrial participation in EU-funded research in the Health sector. Funding scheme:CA, max. 2m/project, up to one project 4.1-2 – Interactions between EU legislation and health research and/or innovation and the effects of its application and implementation on health research and/or innovation. Funding scheme:SA, max. 0.5m/project, one or more projects

62 Activity 4 Actions across the theme 4.1 – CSAs across the theme 4.1-3 - Support for Presidency events. Organisation of supporting actions and events associated to the Presidency of the European Union "…specifically from mid-2013 to 2015 Presidencies, …" Funding scheme:SA, max. 0.1m/project, one or more projects 4.1-4 - Preparing the future for health research and innovation. Funding scheme:SA, max. 0.5m/project, one or more projects 4.1-5: Global initiative on gene-environment interactions in diabetes/obesity in specific populations. Funding scheme:CA, max. 2m/project, up to one project 4.1-6: Mapping chronic non-communicable diseases research activities Funding scheme:CA, max. 1m/project, up to one project

63 Activity 4 Actions across the theme 4.2 – Responding to EU policy needs 4.2-1 - Investigator-driven clinical trials for off-patent medicines using innovative, age-appropriate formulations and/or delivery systems. Funding scheme:CP-FP, max. 6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs. 4.2-2 - Adverse drug reaction research. Funding scheme:CP-FP, max. 3m/project. SME topic: min. 15 % EC contribution to SMEs. 4.2-3 - New methodologies for clinical trials for small population groups. Funding scheme:CP-FP, max. 3m/project.

64 Ethics: overview (1) Two main questions asked on ethics: The necessity to use i.e. personal data, animals, human tissue in order to achieve the scientific objectives set forth in the proposal. Is there an alternative ? Benefit/burden balance of the research project. What will be the impact of this research, not only regarding scientific advance, but also in terms of human dignity as well as social and cultural impact ? All proposals must address these questions.

65 Ethics: overview (2) Applicants must first identify key ethical issues raised by their proposals and explain how they will address them. The main issues are: – Informed Consent – Research on Human embryos/foetuses – Data Protection and Privacy – Research on Animals (the 3Rs: Reduce, Replace, Refine) – Research involving Developing Countries – Dual use (research that could have military applications) 3 areas are excluded from funding: - Human reproductive cloning - Intentional germ line modification (except research relating to cancer of the gonads which can be funded) - Creation of human embryos for research or stem cell procurement (including by means of somatic cell nuclear transfer)

66 5. Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH…

67

68 Other funding opportunities for health research within the Cooperation Specific Programme

69 Call 7(WP2013) Research and Innovation for the benefit of society, with a challenges driven approach to maximize the impact of research funded by the EU 4 main challenges: the main pillars of bio-economySustainable 1) Agriculture and Forestry 2) Safe and Sustainable Food and Health Diets 3) Unlocking the potential of Aquatic Living Resources 4) Sustainable and Competitive Bio-based Industries Broader topics in terms of budget and research developed, leaving greater freedom to the research community Other funding opportunities for health research within the KBBE theme - 2013 Call identifier: FP7-KBBE-2013-7 Proposal submission and evaluation: one-stage procedure. Date of publication: 10 July 2012 Deadline for stage 1 proposals: 5 February 2013 at 17:00 (Brussels local time) Indicative budget: EUR 680 million from the 2013 budget pocaterra@apre.itpocaterra@apre.it – cataldi@apre.itcataldi@apre.it

70 Area 2.2.1 – Consumers Impact of food and nutritional behaviour, lifestyle and the socio-economic environment on depression and proposed remedial actions (LCP, Up to one project ) Area 2.2.2 -Nutrition New technologies to study brain function in relation to eating behaviours and mental well-being (LCP, Up to one project ) Factors influencing the human gut microbiome and its effect on the development of diet related diseases and brain development (LCP, Up to one project )

71 KBBE topics KBBE.2013.2.1-01: Impact of food and nutritional behaviour, lifestyle and the socioeconomic environment on depression and proposed remedial actions (Max 1 CP-IP. Max EC contribution: 6 M) KBBE.2013.2.2-01: New technologies to study brain function in relation to eating Behaviour (Max 1 CP-IP. Max EC contribution: 9 M) KBBE.2013.2.2-02: Factors influencing the human gut microbiome and its effect on the development of diet-related diseases and brain development (Max 1 CP-IP. Max EC contribution: 9 M) KBBE.2013.2.2-03: Food-based solutions for eradication of vitamin D deficiency and health promotion throughout the life cycle (Max 1 CP-IP. Max EC contribution: 6 M)

72 Other funding opportunities for health research within the ICT theme - 2013 WP2013 will support the European Innovation Partnerships on Active and Healthy Ageing (EIP AHA) on Personalized health, active ageing, and independent living ICTs have a catalytic impact in three key areas : Productivity and innovation, by facilitating creativity and management Modernisation of public services, such as health, education and transport. Advances in science and technology, by supporting cooperation and access to information. APERTURA DEADLINE FP7-ICT-2013-1010 Luglio 201215 Gennaio 2013 (734M from budget 2013) FP7-ICT-2013-1118 Settembre 201216 Aprile 2013 (242M from budget 2013) FP7-2013-NMP-ICT-FoF10 Luglio 20124 Dicembre 2012 (70M from budget 2013) FP7-2013-NMP-ENV-ENERGY-ICT-EeB10 Luglio 20124 December 2012 (40M from budget 2013) FP7-2013-ICT-GC10 Luglio 20124 December 2012 (40M from budget 2013) FP7-ICT-2013-SME-DCA10 Luglio 201215 Gennaio 2013 (20M from budget 2013) FP7-ICT-2013-FET-F10 Luglio 201223 Ottobre 2012 (100M from budget 2013) FP7-ICT-2013-C10 Luglio 201212 Marzo 2013 (50M from budget 2013) FP7-ICT-2013-X12 Settembre 201229 Gennaio 2013 (15M from budget 2013) FP7-ICT2013-EU-Japan2 Ottobre 201229 Novembre 2012 (9M from budget 2013) FP7-ICT2013-EU-Brasil10 Luglio 201224 Ottobre 2012 (4M from budget 2013) BUDGET 1455 Million deangelis@apre.itdeangelis@apre.it mercurio@apre.it

73 Challenge 5: ICT for Health, Ageing Well, Inclusion and Governance: Personalized health, active ageing, and independent living - Personalized Guidance Services for lifestyle management and disease prevention. - Personalized Guidance Services for management of co-morbidities and integrated care. - Personalized Services for Independent Living and Active Ageing. - Coordination and Support Actions. Virtual Physiological Human Clinical proof of concept of patient specific computer based models -Personal Health Forecasting. - Coordination and Support Action to develop an RTD roadmap preparing the ground for in-silico clinical trials ICT for smart and personalised inclusion - Accessible and intuitive solutions for personalised interfaces to smart environments and innovative services. - Coordination and Support Actions.

74 Other funding opportunities for health research within the NMP theme - 2013 Work Programme 2013 Priorities desole@apre.it;desole@apre.it borgna@apre.it PPPs (Green Cars, Factories of the Future Energy Efficient Buildings): ~ 36% Cross cutting innovation : ~12% Application-specific innovation : ~26% Raw Materials: ~3% Energy : ~5% Environment/Sustainability: ~9% Health and safety: ~9% NMP.2013.1.2-2Nanotherapeutics to treat bacterial infectious diseases NMP.2013.2.2-1Biomaterials for Advanced Therapies and Medical Devices in the neurological/neuromuscular or cardiovascular fields NMP.2013.2.2-2Biomaterials: Imaging and rapid precise prototyping technology for custom made scaffolds – coordinated call with China

75 Other funding opportunities for health research within the ENV theme - 2013 CHALLENGE 6.4 PROTECTING CITIZENS FROM ENVIRONMENTAL HAZARDS ENV.2013.6.4-1 Assessing individual exposure to environmental stressors and predicting health outcomes: paving the way for an EU-wide assessment (CP, Up to one project ) ENV.2013.6.4-2 Closing gaps of knowledge and reducing exposure to electromagnetic fields (EMF) (CP, Up to one project ) Call identifier: FP7-ENV-2013-two stage Proposal submission and evaluation: two-stage procedure. Date of publication: 10 July 2012 Deadline for stage 1 proposals: 16 October 2012 at 17:00:00 (Brussels local time) Indicative budget: EUR 335.51 million from the 2013 budget materia@apre.itmateria@apre.it; dirosa@apre.itdirosa@apre.it

76 Other funding opportunities for health research within the SSH theme - 2013 Draft Work Programme 2013: SSH.2013.1.3-1 The impact of ageing societies on public finances in Europe Health care, SSH.2013.3.2-2. Early childhood education and care and the cost of inequities SSH.2013.3.2-3. The impact of the third sector on socio-economic development in Europe Call identifier: FP7-SSH-2013-2 Proposal submission and evaluation: one-stage procedure. Date of publication: 12 July 2012 Deadline for stage 1 proposals: 31 January 2013 at 17.00.00 Brussels local time Indicative budget: EUR 72 000000 adunmo@apre.itadunmo@apre.it; longo@apre.itlongo@apre.it

77 Other funding opportunities for health research within the SPACE theme - 2013 Research and development on next generation products and service lines derived from space-borne data in conjunction with in-situ data is to be targeted Activities could target applications on areas like: Health services, or monitoring conditions for vector borne diseases (…) Call identifier: FP7-SPACE-2013-1 Proposal submission and evaluation: one-stage procedure. Date of publication: 12 July 2012 Deadline: 21 November 2012, at 17.00.00, Brussels local time Indicative budget: EUR 126 million adunmo@apre.it Earth-analogue research preparing for space exploration

78 6. Other EU funding opportunities for Health researchers

79

80 7. Sources of information and partners

81

82 www.HealthCompetence.eu An open, pan-European infrastructure for information on research projects & results within Health Science

83

84

85

86 http://www.healthncpnet.eu

87 [FIND A PARTNER]

88 Pagina Salute, Sito APRE www.apre.it/ricerca-europea/VIIPQ/Cooperazione/Salute/Bandi.htm CORDIS: CORDIS: http://cordis.europa.eu/fp7/health/ Fitforhealth: www.fitforhealth.eu Healthncpnet: www.healthncpnet.euwww.healthncpnet.eu Healthcompentence: http://www.healthcompetence.eu/converis/publicweb/area/1353

89 PRESENTAZIONE IN 2 STAGE

90 4. Key issues for success

91 Basics l Eligibility issues - funding scheme, number of partners (esp. for SICA), funding limits, deadlines l Scope of proposal with respects to topic (Relevance)The topic, the whole topic and nothing but the topic also pay attention to introduction in work programme and any specific requirements for industry or international participation l Size and composition of the consortium - beyond the minimum rules, there are no constraints: bring together the competences needed to do the job. Advice for submission & evaluation (1) No bonus points for political correctness or large consortia

92 Basics l Address all 3 criteria – be explicit to evaluators l Address the Ethics issues Clear requirements for information on ethics issues* - you must explain what the issues are in the proposal - and how will you manage them Failing to do so can delay negotiation or even exclude a proposal. l Respect basic rules and guidelines - font size (legibility) and page number limitations (excess pages will not be considered in the evaluation) *Guide for Applicants, Annex 4, section 4. Advice for submission & evaluation (2)

93 Competition is tough : only the best projects get funded the proposal must address the topic and the work programme (not wishful thinking) the consortium of partners must be excellent and competent for the tasks (select the right partners) the proposal must address all 3 criteria, convince the evaluators (dont rely on reputation) and, of course, respect the basic rules. (deadlines, n° of participants, ceilings, length, ethics…) Key factors for success in applying for FP7 funding

94 Thanks for your attention ! Health NCP for ITALY APRE, Agenzia per la promozione della Ricerca Europea Via Cavour 71, Roma buonocore@apre.itbuonocore@apre.it; bergonzi@apre.it


Download ppt "APRE Agenzia per la promozione della Ricerca Europea Caterina Buonocore, Health National Contact Point for Italy, Part of this presentation is taken from."

Similar presentations


Ads by Google